ВАК (Россия)
РИНЦ (Россия)
EBSCO
Регистрационное агентство DOI (США)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Подагра: новые терапевтические стратегии

DOI: https://doi.org/10.29296/25877305-2021-06-04
Номер журнала: 
6
Год издания: 
2021

Н.А. Куницкая, доктор медицинских наук Северо-Западный государственный медицинский университет
им. И.И. Мечникова Минздрава России, Санкт-Петербург E-mail: scvssd@yandex.ru

В настоящее время известно, что длительное отложение уратов требует лечения не только во время острых эпизодов, но и направленного на модуляции активности ключевых ферментов, участвующих метаболизме и экскреции уратов, включая ксантиноксидоредуктазу (КОР) и УРАТ1. В обзоре представлены последние данные об эффективности ингибиторов КОР и урикозурических соединений в снижении уровня мочевой кислоты (МК) как в общем кровотоке, так и в периферических тканях. Основное внимание уделяется влиянию новых ингибиторов КОР на метаболизм МК. Снижение уровня МК через ингибирование КОР связано с ослаблением окислительного стресса, который приводит к эндотелиальной дисфункции, тем самым способствуя развитию сахарного диабета, артериальной гипертензии, атеросклероза и хронической сердечной недостаточности. Таким образом, предотвращение накопления кислородных радикалов, генерируемых КOР, становятся новым направлением в лечении как гиперурикемии, так и подагры.

Ключевые слова: 
подагра
гиперурикемия
окислительный стресс
ингибиторы ксантиноксидоредуктазы
анакинра
канакинумаб
фебуксостат
лезинурад
риноласепт
левотофизопам
пеглотиказа

Для цитирования
Н.А. Куницкая Подагра: новые терапевтические стратегии . Врач, 2021; (6): 16-21 https://doi.org/10.29296/25877305-2021-06-04


Список литературы: 
  1. So A. IL1 inhibition in gout – where are we a decade on? Arthritis Res Ther. 2019; 21 (1): 233. DOI: 10.1186/s13075-019-2027-3
  2. Bardin T., Dalbeth N., Terkeltaub R. et al. Clinical response of tophus and flares to extended use of lesinurad in combination with a xanthine oxidase inhibitor in patients with gout [abstract]. Arthritis Rheumatol. 2016; 68 (suppl. 10).
  3. Bardin T., Keenan R.T., Khanna P.P. et al. Lesinuradin combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR2 study). Ann Rheum Dis. 2017; 76 (5): 811–20. DOI: 10.1136/annrheumdis-2016-209213
  4. Berry C.E., Hare J.M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol Lond. 2004; 555 (Pt. 3): 589–606. DOI: 10.1113/jphysiol.2003.055913
  5. McWherter Ch., Choi1 Y.-J., Serrano R.L. et al. Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP activated protein kinase (AMPK) signaling. Arthritis Res Ther. 2018; 20 (1): 204. DOI: 10.1186/s13075-018-1699-4
  6. Cronstein B.N., Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol. 2013; 19 (1): 19–29. DOI: 10.1097/RHU.0b013e31827d8790
  7. Cronstein B.N., Molad Y., Reibman J. et al., Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995; 96 (2): 994–1002. DOI: 10.1172/JCI118147
  8. Crittenden D.B., Pillinger M.H. New therapies for gout. Annu Rev Med. 2013; 64: 325–37. DOI: 10.1146/annurev-med-080911-105830
  9. Marotto D., De Santis A., Chessa D. et al. A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout. Rheumatol Ther. 2018; 5: 303–10. DOI: 10.1007/s40744-018-0104-8
  10. Dalbeth N., Jones G., Terkeltaub R. et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol. 2017; 69 (9): 1903–13. DOI: 10.1002/art.40159
  11. Doehner W., Anker S.D. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart. 2005; 91: 707–9. DOI: 10.1136/hrt.2004.057190
  12. Fleischmann R., Shen Z., Yeh L.T. et al. Lesinurad (RDEA594), a novel uricosuric agent, in combination with febuxostat shows significant additive urate lowering effects in gout patients with 100% response achieved for all combination dose regimens. Ann Rheum Dis. 2011; 70: 188 (abstract).
  13. Grassi D., Ferri L., Desideri G. et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013; 19: 2432–8. DOI: 10.2174/1381612811319130011
  14. Gustafsson D., Unwin R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164. DOI: 10.1186/1471-2369-14-164
  15. Hande K.R., Noone R.M., Stone W.J. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984; 76: 47–56. DOI: 10.1016/0002-9343(84)90743-5
  16. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med. 2002; 33: 774–97. DOI: 10.1016/s0891-5849(02)00956-5
  17. Harrison R. Physiological roles of xanthine oxidoreductase. Drug Metab Rev. 2004; 36: 363–75. DOI: 10.1081/dmr-120037569
  18. Harzand A., Tamariz L., Hare J.M. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest Heart Fail. 2012; 18 (3): 179–82. DOI: 10.1111/j.1751-7133.2011.00262.x
  19. Jian-Ming L., Yao Q., Chen C. 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout. Biochem Pharmacol. 2013; 86: 1328–37. DOI: 10.1016/j.bcp.2013.08.011
  20. Jones G., Panova E., Day R. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad. Drug Des Devel Ther. 2017; 11: 3077–81. DOI: 10.2147/DDDT.S97959
  21. Stamp L.K., Merriman T.R., Singh J.A. Expert opinion on emerging urate-lowering therapies. Expert Opin Emerg Drugs. 2018; 23 (3): 201–9. DOI: 10.1080/14728214.2018.1527899
  22. Kotz J. The gout pipeline crystallizes. Nat Rev Drug Discov. 2012; 11: 425–6. DOI: 10.1038/nrd3748
  23. Mandell B.F., Edwards N.L., Sundy J.S. et al. Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion. Cleve Clin J Med. 2010; 77: S2–S25. DOI: 10.3949/ccjm.77.s2.01
  24. Pacher P., Nivorozhkin A., Csaba S. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006; 58: 87–114. DOI: 10.1124/pr.58.1.6
  25. Panus P.C., Wright S.A., Chumley P.H. et al. The contribution of vascular endothelial xanthine dehydrogenase/oxidase to oxygen-mediated cell injury. Arch Biochem Biophys. 1992; 294: 695–702. DOI: 10.1016/0003-9861(92)90743-g
  26. Pascart T., Richette P. Investigational drugs for hyperuricemia, an update on recent developments. Expert Opin Investig Drugs. 2018; 27 (5): 437–44. DOI: 10.1080/13543784.2018.1471133
  27. Pascart T., Richette P. Current and future therapies for gout. Expert Opin Pharmacother. 2017; 18 (12): 1201–11. DOI: 10.1080/14656566.2017.1351945
  28. Perez-Ruiz F., Sundy J.S., Miner J.N. et al,; RDEA594-203 Study Group. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016; 75 (6): 1074–80. DOI: 10.1136/annrheumdis-2015-207919
  29. Rajesh M., Mukhopadhyay P., Bátkai S. et al. Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J Cell Mol Med. 2009; 13: 2330–41. DOI: 10.1111/j.1582-4934.2008.00564.x
  30. Robinson P.C., Dalbeth N. Febuxostat for the treatment of hyperuricaemia in gout. Expert Opin Pharmacother. 2018; 19 (11): 1289–99. DOI: 10.1080/14656566.2018.1498842
  31. Saag K.G., Fitz-Patrick D., Kopicko J. et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 2017; 69 (1): 203–12. DOI: 10.1002/art.39840
  32. Saag K., Becker M.A., Storgard C. et al. Examination of Serum Uric Acid (sUA) lowering and safety with extended lesinurad + allopurinol treatment in subjects with gout [abstract]. Arthritis Rheumatol. 2016; 68 (suppl. 10).
  33. Saavedra W.F., Paolocci N., John M.E. St. et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res. 2002; 90: 297–304. DOI: 10.1161/hh0302.104531
  34. Sabán-Ruiz J., Alonso-Pacho A., Fabregate-Fuente M. et al. Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation. Antiinflamm Antiallergy Agents Med Chem. 2013; 12: 94–9. DOI: 10.2174/1871523011312010011
  35. Stamp L.K., O’Donnell J.L., Zhang M. et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011; 63: 412–21. DOI: 10.1002/art.30119
  36. Suresh E., Das P. Recent advances in management of gout. Q J Med. 2012; 105: 407–17. DOI: 10.1093/qjmed/hcr242
  37. Kishimoto T.K. Development of ImmTOR Tolerogenic Nanoparticles for the mitigation of anti-drug antibodies. Front Immunol. 2020; 11: 969. DOI: 10.3389/fimmu.2020.00969
  38. Terkeltaub R.A., Furst D.E., Bennett K. et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel group, dose comparison colchicine study. Arthritis Rheum. 2010; 62: 1060–8. DOI: 10.1002/art.27327
  39. Wilbur K., Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy. 2004; 24: 1784–92. DOI: 10.1592/phco.24.17.1784.52334
  40. Xu X., Hu X., Lu Z. et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail. 2008; 14: 746–53. DOI: 10.1016/j.cardfail.2008.06.006
  41. Zurampic (lesinurad) tablets. FDA Full Prescribing Information. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf